M. Brenner

Focus on Hyperkalemia Management: Expert Consensus and Economic Impacts

J. Butler, B. Pitt, R. Lafayette, 2017 .

All-cause costs increase exponentially with increased chronic kidney disease stage.

K. McGaughey, A. Romero, M. Onuigbo, 2017, The American journal of managed care.

Clinical and Economic Impact of Hyperkalemia in Patients with Chronic Kidney Disease and Heart Failure.

N. Oestreicher, M. Polson, A. Kangethe, 2017, Journal of managed care & specialty pharmacy.

Evaluation of clinical outcomes and costs based on prescribed dose level of renin-angiotensin-aldosterone system inhibitors.

K. McGaughey, M. Epstein, L. Golestaneh, 2016, The American journal of managed care.

The Toxicology Investigators Consortium 2020 Annual Report

Michael V. LeVine, P. Wax, H. Farrar, 2021, Journal of Medical Toxicology.

Managing hyperkalemia in high-risk patients in long-term care.

Steven D. Woods, R. Kumar, B. Smith, 2017, The American journal of managed care.

Clinical and Economic Impact of Hyperkalemia in Patients with Chronic Kidney Disease and Heart Failure.

N. Oestreicher, M. Polson, A. Kangethe, 2017, Journal of managed care & specialty pharmacy.

Clinical and Economic Impact of Hyperkalemia in Patients with Chronic Kidney Disease and Heart Failure.

N. Oestreicher, M. Polson, A. Kangethe, 2017, Journal of managed care & specialty pharmacy.